Chardan Capital maintains Rocket Pharmaceuticals Buy, $11 target
Chardan Capital maintained Rocket Pharmaceuticals at Buy, keeping its $11.00/share price target, according to TradingView News via Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.